J INTS BIO, AACR 2023 – Presentation of preclinical study results of ‘JIN-A04’, an oral target therapy for HER2 exon insertion mutation NSCLC

J INTS BIO announced the poster presentation of its novel, orally administered TKI ‘JIN-A04’ targeting NSCLC with HER2 exon 20 insertion mutation at the annual meeting of the American Association of Cancer Research 2023, which was held in Orlando, USA from April 14 to 19.